Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 4Lymphoma, Large B-Cell, Diffuse 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Hand-Foot Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cancer Related Fatigue 1Breast Neoplasms, Male 1

Interventions

Celecoxib 2Capecitabine 2tegafur-gimeracil-oteracil 1mecobalamin 1liposomal doxorubicin 1Urea 1Tobacco Use Cessation Devices 1Standard of Care 1S 1 (combination) 1Radiotherapy 1Pyridoxine 1Pharmacokinetics 1Medicine, Chinese Traditional 1Low-Level Light Therapy 1Diclofenac 1Brimonidine Tartrate 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hand-Foot Syndrome × Pyridoxine × Clear all
NCT00486213 2015-09-24

Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer

National Cancer Centre, Singapore

Phase 3 Terminated
210 enrolled

Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡